Nirvana Life Sciences Inc.
NIRVF
$0.08
-$0.01-8.07%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 246.40K | 255.10K | 238.30K | 241.20K | 236.60K |
| Depreciation & Amortization | -8.60K | -8.60K | -8.60K | -8.60K | 4.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 237.80K | 246.50K | 229.70K | 232.60K | 261.10K |
| Operating Income | -237.80K | -246.50K | -229.70K | -232.60K | -261.10K |
| Income Before Tax | -250.70K | -266.80K | -246.20K | -260.50K | -397.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.25 | -0.27 | -0.25 | -0.26 | -0.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -300.00 | -300.00 | -200.00 | -300.00 | 400.00 |
| Net Income | -250.80K | -267.00K | -246.30K | -260.70K | -397.40K |
| EBIT | -237.80K | -246.50K | -229.70K | -232.60K | -261.10K |
| EBITDA | -108.20K | -149.00K | -186.50K | -219.50K | -246.80K |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.04 | -0.07 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.04 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 73.40M | 98.81M | 124.11M | 106.11M | 105.50M |
| Average Diluted Shares Outstanding | 73.40M | 98.81M | 124.11M | 106.11M | 105.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |